FDA panel split on Zynquista's benefit-risk profile

An FDA panel was split down the middle about the benefit-risk profile for Zynquista sotagliflozin from Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) as an adjunct to insulin for Type I diabetes.

The agency's Endocrinologic and Metabolic Drugs Advisory Committee voted 8-8 on the question of whether the overall benefits of Zynquista outweighed risks to support approval. ...